Last reviewed · How we verify
Hyperoxia
At a glance
| Generic name | Hyperoxia |
|---|---|
| Also known as | Nocturnal normobaric hyperoxia |
| Sponsor | University of British Columbia |
| Modality | Biologic |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Investigating the Effects of Intermittent Hypoxia-Hyperoxia Treatment (IHHT) in People With Post-Viral Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) to Improve Fatigue, Pain, and Quality of Life by Targeting Mitochondrial Dysfunction and Autonomic Nervous System Impairment (NA)
- Treating Spinal Cord Injury With Early Normobaric Hyperoxia (PHASE2)
- The Association Between Sensory Block Level, Oxygen Therapy, and ORi in Varicose Vein Patients Undergoing Spinal Anesthesia (ORi: Oxygen Reserve Index)
- Oxygen Reserve Index in Laparoscopic Colorectal Surgery
- Normobaric Oxygen Therapy for Individuals With First-Episode Psychosis (NA)
- Oxygen Reserve Index-Guided Oxygen Titration During Surgery in the Beach Chair Position (NA)
- HYPER MIND - Hyperoxia Effects on Cerebral Hemodynamics (NA)
- Cerebral Hemodynamic Effects of Oxygen and Antioxidants (CHEOXANT) (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Hyperoxia CI brief — competitive landscape report
- Hyperoxia updates RSS · CI watch RSS
- University of British Columbia portfolio CI